What is the current market valuation of the US myasthenia gravis-disease market?

The market valuation was $278.76 Million in 2024. Read More

What is the projected market size for the US myasthenia gravis-disease market by 2035?

The projected market size is $709.19 Million by 2035. Read More

What is the expected CAGR for the US myasthenia gravis-disease market during the forecast period 2025 - 2035?

The expected CAGR is 8.86% during the forecast period 2025 - 2035. Read More

Which treatment types are leading in the US myasthenia gravis-disease market?

Immunosuppressants and Monoclonal Antibodies are leading, with valuations of $80.0 Million to $200.0 Million and $70.0 Million to $180.0 Million, respectively. Read More

What are the key diagnostic methods used in the US myasthenia gravis-disease market?

Key diagnostic methods include Blood Tests and MRI, valued at $70.0 Million to $180.0 Million and $60.0 Million to $150.0 Million, respectively. Read More

How do patient demographics impact the US myasthenia gravis-disease market?

Adults represent the largest demographic, with a market valuation of $200.0 Million to $500.0 Million. Read More

What distribution channels are prevalent in the US myasthenia gravis-disease market?

Hospitals and Online Stores are significant distribution channels, valued at $111.5 Million to $284.0 Million and $84.26 Million to $215.19 Million, respectively. Read More

Who are the key players in the US myasthenia gravis-disease market?

Key players include Roche, Bristol-Myers Squibb, Novartis, and Pfizer. Read More

What is the market performance of Cholinesterase Inhibitors in the US myasthenia gravis-disease market?

Cholinesterase Inhibitors have a market valuation ranging from $50.0 Million to $120.0 Million. Read More

What is the significance of intravenous immunoglobulin in the US myasthenia gravis-disease market?

Intravenous immunoglobulin has a valuation of $48.76 Million to $129.19 Million, indicating its relevance in treatment. Read More

US Myasthenia Gravis Disease Market

ID: MRFR/Pharma/15196-HCR

100 Pages

Vikita Thakur

Last Updated: April 24, 2026

US Myasthenia Gravis Disease Market Research Report: Size, Share, Trend Analysis By Treatment Type (Immunosuppressants, Cholinesterase Inhibitors, Monoclonal Antibodies, Plasmapheresis, Intravenous Immunoglobulin), By Diagnosis Method (Electromyography, Blood Tests, CT Scan, MRI, Edrophonium Test), By Patient Demographics (Adults, Children, Elderly) and By Distribution Channel (Hospitals, Pharmacies, Online Stores) - Growth Outlook & Industry Forecast 2025 To 2035

US Myasthenia Gravis Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Treatment Type (USD Million)
  1. 4.1.1 Immunosuppressants
  2. 4.1.2 Cholinesterase Inhibitors
  3. 4.1.3 Monoclonal Antibodies
  4. 4.1.4 Plasmapheresis
  5. 4.1.5 Intravenous Immunoglobulin
2. 4.2 Life Sciences, BY Diagnosis Method (USD Million)
  1. 4.2.1 Electromyography
  2. 4.2.2 Blood Tests
  3. 4.2.3 CT Scan
  4. 4.2.4 MRI
  5. 4.2.5 Edrophonium Test
3. 4.3 Life Sciences, BY Patient Demographics (USD Million)
  1. 4.3.1 Adults
  2. 4.3.2 Children
  3. 4.3.3 Elderly
4. 4.4 Life Sciences, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Pharmacies
  3. 4.4.3 Online Stores
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Eisai (JP)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Teva (IL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD
4. 6.4 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Treatment Type (USD Million, 2025-2035)

Immunosuppressants
Cholinesterase Inhibitors
Monoclonal Antibodies
Plasmapheresis
Intravenous Immunoglobulin

Life Sciences By Diagnosis Method (USD Million, 2025-2035)

Electromyography
Blood Tests
CT Scan
MRI
Edrophonium Test

Life Sciences By Patient Demographics (USD Million, 2025-2035)

Adults
Children
Elderly

Life Sciences By Distribution Channel (USD Million, 2025-2035)

Hospitals
Pharmacies
Online Stores

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”